Hazell A S, Butterworth R F
Neuroscience Research Unit, Center Hospitalier de l'Université de Montréal, Quebec, Canada.
Proc Soc Exp Biol Med. 1999 Nov;222(2):99-112. doi: 10.1046/j.1525-1373.1999.d01-120.x.
Hepatic encephalopathy (HE) is a neuropsychiatric disorder that occurs in both acute and chronic liver failure. Although the precise pathophysiologic mechanisms responsible for HE are not completely understood, a deficit in neurotransmission rather than a primary deficit in cerebral energy metabolism appears to be involved. The neural cell most vulnerable to liver failure is the astrocyte. In acute liver failure, the astrocyte undergoes swelling resulting in increased intracranial pressure; in chronic liver failure, the astrocyte undergoes characteristic changes known as Alzheimer type II astrocytosis. In portal-systemic encephalopathy resulting from chronic liver failure, astrocytes manifest altered expression of several key proteins and enzymes including monoamine oxidase B, glutamine synthetase, and the so-called peripheral-type benzodiazepine receptors. In addition, expression of some neuronal proteins such as monoamine oxidase A and neuronal nitric oxide synthase are modified. In acute liver failure, expression of the astrocytic glutamate transporter GLT-1 is reduced, leading to increased extracellular concentrations of glutamate. Many of these changes have been attributed to a toxic effect of ammonia and/or manganese, two substances that are normally removed by the hepatobiliary route and that in liver failure accumulate in the brain. Manganese deposition in the globus pallidus in chronic liver failure results in signal hyperintensity on T1-weighted Magnetic Resonance Imaging and may be responsible for the extrapyramidal symptoms characteristic of portal-systemic encephalopathy. Other neurotransmitter systems implicated in the pathogenesis of hepatic encephalopathy include the serotonin system, where a synaptic deficit has been suggested, as well as the catecholaminergic and opioid systems. Further elucidation of the precise nature of these alterations could result in the design of novel pharmacotherapies for the prevention and treatment of hepatic encephalopathy.
肝性脑病(HE)是一种发生于急性和慢性肝衰竭的神经精神障碍。尽管导致HE的确切病理生理机制尚未完全明确,但似乎涉及神经传递缺陷而非脑能量代谢的原发性缺陷。对肝衰竭最敏感的神经细胞是星形胶质细胞。在急性肝衰竭中,星形胶质细胞肿胀导致颅内压升高;在慢性肝衰竭中,星形胶质细胞会发生特征性变化,即所谓的II型阿尔茨海默样星形细胞增生。在慢性肝衰竭所致的门体性脑病中,星形胶质细胞表现出几种关键蛋白质和酶的表达改变,包括单胺氧化酶B、谷氨酰胺合成酶以及所谓的外周型苯二氮䓬受体。此外,一些神经元蛋白如单胺氧化酶A和神经元型一氧化氮合酶的表达也会发生改变。在急性肝衰竭中,星形胶质细胞谷氨酸转运体GLT - 1的表达降低,导致细胞外谷氨酸浓度升高。这些变化许多都归因于氨和/或锰的毒性作用,这两种物质通常经肝胆途径清除,在肝衰竭时会在脑内蓄积。慢性肝衰竭时苍白球中的锰沉积导致T1加权磁共振成像信号高增强,可能是门体性脑病锥体外系症状的原因。其他与肝性脑病发病机制相关的神经递质系统包括血清素系统,有人提出该系统存在突触缺陷,还有儿茶酚胺能和阿片样物质系统。进一步阐明这些改变的确切性质可能会带来预防和治疗肝性脑病的新型药物疗法。